<DOC>
	<DOCNO>NCT01533051</DOCNO>
	<brief_summary>The aim study investigate off-treatment sustained virological biochemical response chronic hepatitis B patient follow guideline Asian Pacific Association Study Liver ( APASL ) Korea .</brief_summary>
	<brief_title>Prospective Observational Cohort Study Durability Anti-viral Therapy Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>In recommendation Asian PAcific Association Study Liver ( APASL ) , antiviral drug recommend stop HBeAg seroconversion develop 6 month among HBeAg-positive patietns . For HBeAg-negative patient , APASL consensus recommend stop anti-viral treatment HBV DNA remain undetectable three separate occasion 6 month apart . Nontheless , approximately 25 % 50 % patient still develop hepatitis relapse stop anti-viral therapy even recommendation follow . In study , investigator aim investigated off-treatment sustain response chronic hepatitis B parients follow stop anti-viral treatment guideline Korea .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>More 20 year old Chronic hepatitis B patient antiviral therapy 1 . In HBeAgpositive patient ; HBeAg seroconversion undetectable HBV DNA document two separate occasion least 6 month 2 . In HBeAgnegative patient ; undetectable HBV DNA document three separate occasion 6 month apart Patients chronic liver disease due hemochromatosis , autoimmune hepatitis , druginduced hepatitis , thalassemia Patients suffer chronic medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Nucleos ( ) ide analogue</keyword>
	<keyword>Antiviral treatment</keyword>
	<keyword>Korea</keyword>
</DOC>